webmaster
-
Quant Biomarkers Secures Approval for HKD 6 Million Funding under Hong Kong’s HSITP IGNITE Programme
More Details: Quant Biomarkers Secures Approval for HKD 6 Million Funding under Hong Kong’s HSITP IGNITE ProgrammeBasel / Hong Kong – March 2026 Quant Biomarkers (HK) Limited, a subsidiary of Quant Biomarkers AG, Switzerland, has received approval for admission to the IGNITE (Life & Health Technology) programme at the Hong Kong–Shenzhen Innovation and Technology Park (HSITP), including a milestone-based non-dilutive funding of approximately USD 750,000. The programme supports high-potential health technology…
-
Quant Biomarkers AG partners with CHUV and UZH research teams and secures Innosuisse funding to advance clinically actionable cardio-kidney-metabolic biomarkers
More Details: Quant Biomarkers AG partners with CHUV and UZH research teams and secures Innosuisse funding to advance clinically actionable cardio-kidney-metabolic biomarkersBasel, Switzerland – January 2026 – Quant Biomarkers AG has secured approximately CHF 1 million in non-dilutive grant funding from Innosuisse to support the development and clinical validation of a biomarker test for earlier detection, progression assessment, and treatment monitoring of chronic kidney disease (CKD). The Innovation project supported by Innosuisse is advancing cutting-edge translational…